Pre-hospital stroke monitoring past, present, and future: a perspective.
| Autor: | Ben Pazi H; Avertto Medical Ltd., Aderet, Israel., Jahashan S; Neurosurgery, Galilee Medical Center, Nahariya, Israel., Har Nof S; Neurosurgery, Rabin Medical Center, Petach Tikva, Israel., Zibman S; Avertto Medical Ltd., Aderet, Israel., Yanai-Kohelet O; Avertto Medical Ltd., Aderet, Israel., Prigan L; Avertto Medical Ltd., Aderet, Israel., Intrator N; Neurosteer Inc., New York, NY, United States., Bornstein NM; Stroke Unit, Neurology, Shaare Zedek Medical Center, Jerusalem, Israel.; Tel Aviv Medical School, Tel Aviv University, Tel Aviv, Israel., Ribo M; Stroke Unit, Neurology, Barcelona, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in neurology [Front Neurol] 2024 Mar 22; Vol. 15, pp. 1341170. Date of Electronic Publication: 2024 Mar 22 (Print Publication: 2024). |
| DOI: | 10.3389/fneur.2024.1341170 |
| Abstrakt: | Integrated brain-machine interface signifies a transformative advancement in neurological monitoring and intervention modalities for events such as stroke, the leading cause of disability. Historically, stroke management relied on clinical evaluation and imaging. While today's stroke landscape integrates artificial intelligence for proactive clinical decision-making, mainly in imaging and stroke detection, it depends on clinical observation for early detection. Cardiovascular monitoring and detection systems, which have become standard throughout healthcare and wellness settings, provide a model for future cerebrovascular monitoring and detection. This commentary reviews the progression of continuous stroke monitoring, spotlighting contemporary innovations and prospective avenues, and emphasizes the influential roles of cutting-edge technologies in shaping stroke care. Competing Interests: HB, SZ, OY-K, and LP were employed by the company Avertto Medical Ltd., which develops AverttoTM, a continuous carotid monitoring system. NI was employed by Neurosteer Inc. SJ, SH, and MR are PIs in clinical studies by Avertto. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Ben Pazi, Jahashan, Har Nof, Zibman, Yanai-Kohelet, Prigan, Intrator, Bornstein and Ribo.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|